{
    "xml": "<topic id=\"PHP5559\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/docetaxel\" basename=\"docetaxel\" title=\"DOCETAXEL\">\n<title>DOCETAXEL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_516\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/taxanes/docetaxel\">Docetaxel</xref>\n</p>\n<data name=\"vtmid\">108806006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_780680770\" title=\"Taxanes\">Taxanes</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP63501\" outputclass=\"indicationsAndDose\" rev=\"1.29\" parent=\"/drugs/docetaxel\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjuvant treatment of operable node-positive and operable node-negative breast cancer (in combination with doxorubicin and cyclophosphamide)</p>\n<p outputclass=\"therapeuticIndication\">Initial chemotherapy of locally advanced or metastatic breast cancer (with doxorubicin)</p>\n<p outputclass=\"therapeuticIndication\">Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline or an alkylating drug has failed (monotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline has failed (with capecitabine)</p>\n<p outputclass=\"therapeuticIndication\">Initial chemotherapy of metastatic breast cancer which overexpresses human epidermal growth factor-2 (with trastuzumab)</p>\n<p outputclass=\"therapeuticIndication\">Locally advanced or metastatic non-small cell lung cancer where first-line chemotherapy has failed</p>\n<p outputclass=\"therapeuticIndication\">Unresectable, locally advanced or metastatic non-small cell lung cancer (with cisplatin)</p>\n<p outputclass=\"therapeuticIndication\">Hormone-resistant metastatic prostate cancer (in combination with prednisone or prednisolone)</p>\n<p outputclass=\"therapeuticIndication\">Initial treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction (with cisplatin and fluorouracil)</p>\n<p outputclass=\"therapeuticIndication\">Induction treatment of locally advanced squamous cell carcinoma of the head and neck (with cisplatin and fluorouracil)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63632\" outputclass=\"cautions\" rev=\"1.22\" parent=\"/drugs/docetaxel\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">consult product literature</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP63485\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/docetaxel\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (docetaxel).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63427\" outputclass=\"sideEffects\" rev=\"1.44\" parent=\"/drugs/docetaxel\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">cystoid macular oedema</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">fatal respiratory disorders</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal toxicity</ph>; <ph outputclass=\"sideEffect\">heart failure</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">peripheral neurotoxicity</ph>; <ph outputclass=\"sideEffect\">persistent fluid retention (commonly as leg oedema that worsens during treatment) can be resistant to treatment</ph>; <ph outputclass=\"sideEffect\">severe skin reactions</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Consult product literature for monitoring and management of side effects.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions and fluid retention</p>\n<p>Pretreatment with dexamethasone by mouth is recommended for reducing fluid retention and hypersensitivity reactions (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63611\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/docetaxel\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>.</p>\n<p>Reduced fertility in <i>animal</i> studies.</p>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;manufacturer advises effective contraception for men and women during treatment, and for at least 6 months after stopping treatment in men.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63472\" outputclass=\"pregnancy\" parent=\"/drugs/docetaxel\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (toxicity in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63645\" outputclass=\"breastFeeding\" parent=\"/drugs/docetaxel\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63519\" outputclass=\"hepaticImpairment\" parent=\"/drugs/docetaxel\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose according to liver enzymes (consult product literature).</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Monitor liver function in hepatic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63359\" outputclass=\"nationalFunding\" rev=\"1.21\" parent=\"/drugs/docetaxel\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA101</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)</p>\r\n<p>Docetaxel is an option for hormone-refractory metastatic prostate cancer and a Karnofsky score of at least 60% [Karnofsky score is a measure of the ability to perform ordinary tasks].</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA101\">www.nice.org.uk/TA101</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA109</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)</p>\r\n<p>Docetaxel, when given concurrently with doxorubicin and cyclophosphamide (TAC regimen), is recommended as an option for the adjuvant treatment of women with early node-positive breast cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA109\">www.nice.org.uk/TA109</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised that docetaxel (<i>Taxotere</i>\r\n<tm tmtype=\"reg\"/>) in combination with cisplatin and fluorouracil is accepted for restricted use within NHS Scotland for the induction treatment of patients with unresectable (May 2007) and resectable (June 2008) locally advanced squamous cell carcinoma of the head and neck.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5559-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/docetaxel\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75525\" title=\"Solution for infusion\" namespace=\"/drugs/docetaxel/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_516\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/taxanes/docetaxel\" title=\"Docetaxel\" count=\"1\" rel=\"link\">Docetaxel</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75525\" namespace=\"/drugs/docetaxel/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5559",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/docetaxel",
    "basename": "docetaxel",
    "title": "DOCETAXEL",
    "interactants": [
        {
            "id": "bnf_int_516",
            "label": "Docetaxel"
        }
    ],
    "vtmid": "108806006",
    "drugClassification": [
        "Taxanes"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Adjuvant treatment of operable node-positive and operable node-negative breast cancer (in combination with doxorubicin and cyclophosphamide)",
                        "html": "Adjuvant treatment of operable node-positive and operable node-negative breast cancer (in combination with doxorubicin and cyclophosphamide)"
                    },
                    {
                        "textContent": "Initial chemotherapy of locally advanced or metastatic breast cancer (with doxorubicin)",
                        "html": "Initial chemotherapy of locally advanced or metastatic breast cancer (with doxorubicin)"
                    },
                    {
                        "textContent": "Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline or an alkylating drug has failed (monotherapy)",
                        "html": "Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline or an alkylating drug has failed (monotherapy)"
                    },
                    {
                        "textContent": "Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline has failed (with capecitabine)",
                        "html": "Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline has failed (with capecitabine)"
                    },
                    {
                        "textContent": "Initial chemotherapy of metastatic breast cancer which overexpresses human epidermal growth factor-2 (with trastuzumab)",
                        "html": "Initial chemotherapy of metastatic breast cancer which overexpresses human epidermal growth factor-2 (with trastuzumab)"
                    },
                    {
                        "textContent": "Locally advanced or metastatic non-small cell lung cancer where first-line chemotherapy has failed",
                        "html": "Locally advanced or metastatic non-small cell lung cancer where first-line chemotherapy has failed"
                    },
                    {
                        "textContent": "Unresectable, locally advanced or metastatic non-small cell lung cancer (with cisplatin)",
                        "html": "Unresectable, locally advanced or metastatic non-small cell lung cancer (with cisplatin)"
                    },
                    {
                        "textContent": "Hormone-resistant metastatic prostate cancer (in combination with prednisone or prednisolone)",
                        "html": "Hormone-resistant metastatic prostate cancer (in combination with prednisone or prednisolone)"
                    },
                    {
                        "textContent": "Initial treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction (with cisplatin and fluorouracil)",
                        "html": "Initial treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction (with cisplatin and fluorouracil)"
                    },
                    {
                        "textContent": "Induction treatment of locally advanced squamous cell carcinoma of the head and neck (with cisplatin and fluorouracil)",
                        "html": "Induction treatment of locally advanced squamous cell carcinoma of the head and neck (with cisplatin and fluorouracil)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "consult product literature",
                "html": "consult product literature"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (docetaxel).",
                "html": "<p>Appendix 1 (docetaxel).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cystoid macular oedema",
                        "html": "cystoid macular oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fatal respiratory disorders",
                        "html": "fatal respiratory disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal toxicity",
                        "html": "gastro-intestinal toxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "heart failure",
                        "html": "heart failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neurotoxicity",
                        "html": "peripheral neurotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "persistent fluid retention (commonly as leg oedema that worsens during treatment) can be resistant to treatment",
                        "html": "persistent fluid retention (commonly as leg oedema that worsens during treatment) can be resistant to treatment",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe skin reactions",
                        "html": "severe skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Consult product literature for monitoring and management of side effects.",
                "html": "<p>Consult product literature for monitoring and management of side effects.</p>"
            },
            {
                "type": "advice",
                "title": "Hypersensitivity reactions and fluid retention",
                "textContent": "Pretreatment with dexamethasone by mouth is recommended for reducing fluid retention and hypersensitivity reactions (consult product literature).",
                "html": "<p>Pretreatment with dexamethasone by mouth is recommended for reducing fluid retention and hypersensitivity reactions (consult product literature).</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": ".\n\nReduced fertility in animal studies.\n\nExclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;manufacturer advises effective contraception for men and women during treatment, and for at least 6 months after stopping treatment in men.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>.</p><p>Reduced fertility in <i>animal</i> studies.</p><p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;manufacturer advises effective contraception for men and women during treatment, and for at least 6 months after stopping treatment in men.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (toxicity in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (toxicity in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose according to liver enzymes (consult product literature).",
                "html": "<p>Reduce dose according to liver enzymes (consult product literature).</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor liver function in hepatic impairment.",
                "html": "<p>Monitor liver function in hepatic impairment.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA101",
                        "label": "www.nice.org.uk/TA101"
                    }
                ],
                "fundingIdentifier": "NICE TA101",
                "textContent": "Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006) Docetaxel is an option for hormone-refractory metastatic prostate cancer and a Karnofsky score of at least 60% [Karnofsky score is a measure of the ability to perform ordinary tasks].\n\nwww.nice.org.uk/TA101",
                "html": "<p outputclass=\"title\">Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)</p> <p>Docetaxel is an option for hormone-refractory metastatic prostate cancer and a Karnofsky score of at least 60% [Karnofsky score is a measure of the ability to perform ordinary tasks].</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA101\">www.nice.org.uk/TA101</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA109",
                        "label": "www.nice.org.uk/TA109"
                    }
                ],
                "fundingIdentifier": "NICE TA109",
                "textContent": "Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) Docetaxel, when given concurrently with doxorubicin and cyclophosphamide (TAC regimen), is recommended as an option for the adjuvant treatment of women with early node-positive breast cancer.\n\nwww.nice.org.uk/TA109",
                "html": "<p outputclass=\"title\">Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)</p> <p>Docetaxel, when given concurrently with doxorubicin and cyclophosphamide (TAC regimen), is recommended as an option for the adjuvant treatment of women with early node-positive breast cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA109\">www.nice.org.uk/TA109</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75525",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_516",
                "label": "Docetaxel",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75525",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}